E-cigarette maker welcomes FDA challenge
MIAMI Despite the ongoing battle between the Food and Drug Administration and electronic cigarette makers, one manufacturer welcomes the challenge as a chance to present its product as a healthier alternative to traditional tobacco.
Green Smoke said it has created an electronic cigarette designed to simulate the smoking experience without carcinogenics. Instead, it emits an odorless vapor of mostly steam, with ingredients like nicotine, water, propylene glycol (an additive used in cake mixes) and others. The nicotine also is available in different strengths.
The company also added that the price for the electronic cigarettes are more cost-efficient than regular tobacco products, with cigarette starter kits ranging from $109 to $270. The starter kits include nicotine cartridges, rechargeable cigarette batteries, home charger and more.
WHO: H1N1 to be included in next year’s seasonal flu vaccine
GENEVA During a press conference held Thursday, the World Health Organization updated the status of the novel H1N1 pandemic and announced that the novel H1N1 influenza vaccine would be incorporated into next season’s seasonal flu vaccine.
The triumvirate vaccine will include protection against the novel H1N1 virus, an H3N2 strain and a type-B virus.
“What the scientists said was that in the past year, the overwhelming number of influenza viruses that were isolated around the world were the pandemic H1N1 virus,” Keiji Fukuda, special adviser to the WHO’s director-general for pandemic influenza, told reporters. “The experts believe based on this information that these viruses will continue to be one of the dominant viruses in wide circulation in the coming fall and winter season in the northern hemisphere.”
However, substituting the pandemic H1N1 virus in place of last year’s seasonal H1N1 inoculation does not suggest that the novel H1N1 pandemic has concluded its course, Fukuda warned. “The recommendation to put the pandemic virus in the upcoming vaccine really means that this has been a dominant virus. And it is expected that it will continue to be a significant virus, circulating around the world as we head into the winter or the coming winter in 2010 and 2011.”
WHO will be convening its Emergency Committee under the International Health Regulations Feb. 23, Fukuda added, noting that the meeting will be both to review the overall epidemiologic and virologic situation, and to provide some guidance to WHO as to whether we can consider ourselves in “the so-called post-peak period.”
The post-peak period is a transition period in which WHO continues to expect to see pandemic activity occur at different levels in different parts of the world, but that the worst has come to pass, Fukuda said. WHO will not be removing the “pandemic” status, however, Fukuda added. “The practical effect of indicating that we are in a post-peak period is really to give a broad signal to the world that even though we may continue to see pandemic activity that we expect that we are transitioning more towards a normal level.”
The highest levels of pandemic activity currently are occurring in parts of Eastern Europe, some parts of Northern Africa and parts of Asia.
New research finds ibuprofen may lower risk of Parkinson’s disease
ST. PAUL, Minn. Ibuprofen may soon join aspirin as a daily analgesic prophylactic.
According to new research released Wednesday, supplementation with ibuprofen may reduce the risk of developing Parkinson’s disease.
The research involved 136,474 people who did not have Parkinson’s disease at the beginning of the research. Participants were asked about their use of non-steroid anti-inflammatory drugs, including aspirin, ibuprofen and acetaminophen. After six years, 293 participants had developed Parkinson’s disease.
The study found regular users of ibuprofen were 40% less likely to develop Parkinson’s disease than people who didn’t take ibuprofen. Also, people who took higher amounts of ibuprofen were less likely to develop Parkinson’s disease than people who took smaller amounts of the drug. The results were the same regardless of age, smoking and caffeine intake, researchers noted.
“Ibuprofen was the only NSAID linked to a lower risk of Parkinson’s,” stated Xiang Gao, of the Harvard School of Public Health in Boston. “Other NSAIDs and analgesics, including aspirin and acetaminophen, did not appear to have any effect on lowering a person’s risk of developing Parkinson’s. More research is needed as to how and why ibuprofen appears to reduce the risk of Parkinson’s disease, which affects up to one million people in the United States.”
The research will be presented at the American Academy of Neurology’s 62nd Annual Meeting in Toronto in April.
The study was supported by the National Institute of Neurological Disorders and Stroke.